- Home
- NATR vs PBYI Comparison
NATR vs PBYI Comparison
Compare NATR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATR | PBYI |
|---|---|---|
| Founded | 1972 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.7M | 343.9M |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NATR | PBYI |
|---|---|---|
| Price | $21.89 | $7.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.33 | N/A |
| AVG Volume (30 Days) | 78.8K | ★ 252.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $480,144,000.00 | $27,685,000.00 |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $75.52 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $12.97 | $3.03 |
| 52 Week High | $28.14 | $7.90 |
Technical Indicators
Market Signals| Indicator | NATR | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 28.48 | 47.25 |
| Support Level | $21.27 | $5.75 |
| Resistance Level | $27.74 | $7.25 |
| Average True Range (ATR) | 1.24 | 0.36 |
| MACD | -0.25 | -0.05 |
| Stochastic Oscillator | 13.40 | 35.43 |
Price Performance
Historical ComparisonAbout NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.